Plain-English translation of NCT06411691 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a combination treatment for advanced colorectal and pancreatic cancer. The main component is a vaccine called SPL mKRASvax, which is designed to teach your immune system to recognize and attack cancer cells that have a specific genetic mutation. This medication is given alongside two other drugs ( and ) that help boost your immune system's ability to fight the cancer.
Many people with advanced colorectal or pancreatic cancer develop resistance to standard chemotherapy treatments. Researchers believe that combining a personalized cancer vaccine with immune-boosting drugs may help your body's own immune system recognize and destroy remaining cancer cells more effectively than chemotherapy alone.
You likely qualify if…
You likely don't qualify if…
You would receive injections of the vaccine combined with the two immune-boosting medications, likely given over multiple visits at the cancer center. During the trial, you would have blood tests, imaging scans, and possibly tumor biopsies to monitor how the treatment is working and how your immune system is responding. The study also involves close monitoring of your health and any side effects you may experience.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States